Amoy Diagnostics Co Ltd
SZSE:300685
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.78
27.15
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Amoy Diagnostics Co Ltd stock under the Base Case scenario is 28 CNY. Compared to the current market price of 24.8 CNY, Amoy Diagnostics Co Ltd is Undervalued by 11%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Amoy Diagnostics Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Amoy Diagnostics Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Amoy Diagnostics Co Ltd
Balance Sheet Decomposition
Amoy Diagnostics Co Ltd
Current Assets | 1.7B |
Cash & Short-Term Investments | 1.1B |
Receivables | 591.8m |
Other Current Assets | 43.5m |
Non-Current Assets | 296.4m |
Long-Term Investments | 22.4m |
PP&E | 189.3m |
Intangibles | 47.1m |
Other Non-Current Assets | 37.6m |
Current Liabilities | 212m |
Accounts Payable | 17.7m |
Accrued Liabilities | 64.4m |
Short-Term Debt | 6.1m |
Other Current Liabilities | 123.9m |
Non-Current Liabilities | 12.6m |
Long-Term Debt | 3.7m |
Other Non-Current Liabilities | 8.8m |
Earnings Waterfall
Amoy Diagnostics Co Ltd
Revenue
|
1.2B
CNY
|
Cost of Revenue
|
-186.1m
CNY
|
Gross Profit
|
997.8m
CNY
|
Operating Expenses
|
-659.6m
CNY
|
Operating Income
|
338.2m
CNY
|
Other Expenses
|
-23.2m
CNY
|
Net Income
|
315m
CNY
|
Free Cash Flow Analysis
Amoy Diagnostics Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Amoy Diagnostics Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Amoy Diagnostics Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Amoy Diagnostics Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Amoy Diagnostics Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Amoy Diagnostics Co Ltd
According to Wall Street analysts, the average 1-year price target for Amoy Diagnostics Co Ltd is 30.85 CNY with a low forecast of 24.08 CNY and a high forecast of 37.8 CNY.
Dividends
Current shareholder yield for Amoy Diagnostics Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Amoy Diagnostics Co., Ltd. engages in the research, development, production and sale of tumour precision medical molecular diagnostic products. The company is headquartered in Xiamen, Fujian and currently employs 1,096 full-time employees. The company went IPO on 2017-08-02. The firm provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The firm also provides data software to capture and analyze gene sequencing data. The firm provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
Contact
IPO
Employees
Officers
The intrinsic value of one Amoy Diagnostics Co Ltd stock under the Base Case scenario is 28 CNY.
Compared to the current market price of 24.8 CNY, Amoy Diagnostics Co Ltd is Undervalued by 11%.